Phathom Pharmaceuticals, Inc. (PHAT)

USD 7.99

(-4.54%)

Market Cap (In USD)

546.33 Million

Revenue (In USD)

682 Thousand

Net Income (In USD)

-201.59 Million

Avg. Volume

904.03 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.065-19.71
PE
-
EPS
-
Beta Value
0.718
ISIN
US71722W1071
CUSIP
71722W107
CIK
1783183
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Terrie J. Curran
Employee Count
-
Website
https://www.phathompharma.com
Ipo Date
2019-10-25
Details
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.